Cover Kidney News
Volume/Issue:
Volume 14: Issue 4
Page:
25–26
Publication Date:
01 Apr 2022
Online Publication Date:
06 Apr 2022
Figure 1

Beneficial effects of SGLT2 inhibition in heart failure
  • 1.

    van der Aart-van der Beek AB, et al. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol [published online ahead of print February 10, 2022]. doi: 10.1038/s41581-022-00535-6; https://www.nature.com/articles/s41581-022-00535-6

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Wichaiyo S, Saengklub N. Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: What is the evidence? Heart Fail Rev [published online ahead of print February 18, 2022]. doi: 10.1007/s10741-022-10220-2; https://link.springer.com/article/10.1007/s10741-022-10220-2

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Tomasoni D, et al. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail [published online ahead of print December 10, 2021]. doi: 10.1002/ejhf.2397; https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2397

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Packer M, et al. Empagliflozin and major renal outcomes in heart failure. N Engl J Med 2021; 385:1531–1533. doi: 10.1056/NEJMc2112411

  • 5.

    Murphy SP, et al. Heart failure with reduced ejection fraction: A review. JAMA 2020; 324:488–504. doi: 10.1001/jama.2020.10262

Editorial Type:
Special Section

Mechanism of Heart Protection by SGLT2 Inhibitors, Direct and Indirect Effects

Jianxiang Xue Jianxiang Xue, PhD, and Timo Rieg, MD, are with the Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, and Dr. Rieg is also with the James A. Haley Veterans' Hospital, Tampa, FL.

Search for other papers by Jianxiang Xue in
Current site
Google Scholar
PubMed Close
and
Timo Rieg Jianxiang Xue, PhD, and Timo Rieg, MD, are with the Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, and Dr. Rieg is also with the James A. Haley Veterans' Hospital, Tampa, FL.

Search for other papers by Timo Rieg in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 14: Issue 4
Publication Date:
01 Apr 2022
Page:
25–26
Restricted access
Save